DULOXETINE CAPSULE (DELAYED RELEASE)

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

DULOXETINE (DULOXETINE HYDROCHLORIDE)

Доступна з:

ALTAMED PHARMA

Код атс:

N06AX21

ІПН (Міжнародна Ім'я):

DULOXETINE

Дозування:

60MG

Фармацевтична форма:

CAPSULE (DELAYED RELEASE)

Склад:

DULOXETINE (DULOXETINE HYDROCHLORIDE) 60MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

30/100/1000

Тип рецепту:

Prescription

Терапевтична области:

SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS

Огляд продуктів:

Active ingredient group (AIG) number: 0152350002; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2023-02-06

Характеристики продукта

______________________________________________________________________________
_Duloxetine Product Monograph_
_ Page 1 of 82_
PRODUCT MONOGRAPH
PR DULOXETINE
Duloxetine Delayed-Release Capsules
Duloxetine (as duloxetine hydrochloride)
30 mg and 60 mg
Manufacturer’s standard
ANALGESIC/ANTIDEPRESSANT/ANXIOLYTIC
Altamed Pharma
1565, boul. Lionel-Boulet
Varennes, Quebec
J3X 1P7
Submission Control No.: 271223
DATE OF REVISION:
FEB
06,
2023
______________________________________________________________________________
_Duloxetine Product Monograph_
_ Page 2 of 82_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT
INFORMATION......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
................................................................................................
5
WARNINGS AND PRECAUTIONS
...............................................................................
6
ADVERSE REACTIONS
................................................................................................
18
DRUG INTERACTIONS
................................................................................................
37
DOSAGE AND ADMINISTRATION
............................................................................
40
OVERDOSAGE
..............................................................................................................
43
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 44
STORAGE AND STABILITY
........................................................................................
47
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................ 47
PART II: SCIENTIFIC INFORMATION
..............................................................................
49
PHARMACEUTICAL INFORMATION
..............................